Form 4: Director John M. Siebert Reports Supernus Pharmaceuticals Stock Transaction
SEC Form 4 Filing
Director John M. Siebert reports the acquisition and disposal of Supernus Pharmaceuticals common stock and restricted stock units on February 23, 2024.
Summary
- On February 23, 2024, John M. Siebert, a director of Supernus Pharmaceuticals, acquired 3,886 shares of common stock.
- On the same day, Siebert disposed of 3,886 restricted stock units, which vested and were settled in common stock.
- Following these transactions, Siebert beneficially owns 87,943 shares of Supernus common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock transactions by a company director, with no inherent positive or negative sentiment.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.
Stakeholder Impact
- The transaction provides transparency to shareholders regarding insider activity.
Key Dates
| Date | Description |
|---|---|
| 02/23/2024 | Date of transaction: acquisition of common stock and disposal of restricted stock units. |
| 02/27/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.